INVESTIGATORS have found what may be an association between renal cell carcinoma (RCC) and multiple myeloma (MM).

BEVACIZUMAB USED in combination with interferon alfa as a first-line treatment for metastatic renal cell carcinoma (RCC) nearly doubled progression-free survival in patients taking part in an international phase III trial.

Rexahn Pharmaceuticals, Inc., of Rockville, Md., has announced that it has received approval to begin a phase II study for its lead oncology compound, Archexin (formerly known as RX-0201), in patients with advanced renal cell carcinoma.

Torisel (temsirolimus), an enzyme inhibitor, has received approval for advanced renal cell carcinoma (RCC) following a study of 626 patients.

Renal cell carcinoma (RCC) diagnosed in patients at a younger age has more favorable histopathologic features and survival compared with RCC diagnosed in older patients, according to researchers.

Sorafenib treatment doubles progression-free survival in patients with advanced renal cell carcinoma, regardless of whether they have received prior cytokine therapy.

New labeling of Sutent (sunitinib malate, Pfizer) has been approved that includes first-line treatment of advanced renal cell carcinoma (RCC).

SAN DIEGO—Stereotactic radiosurgery produces early and durable responses in renal cell carcinoma (RCC) patients with either previously untreated spinal metastases or spinal metastases that have recurred after prior radiotherapy, researchers announced here at the 2007 Annual Meeting of the American Academy of Orthopedic Surgeons.

The FDA issued a public health advisory outlining new safety information, including revised product labeling about erythropoiesis-stimulating agents (ESAs). The drugs affected by the safety update are darbepoetin alfa (Aranesp) and epoetin alfa (Epogen and Procrit).

TWO RELATIVELY new oral agents can improve outcomes for patients with metastatic renal cell carcinoma (RCC), according to recent reports. The drugs, sunitinib and sorafenib, inhibit enzymes that promote angiogenesis and thus may act by disrupting tumor vasculature.